Pharmaceutical Care for Diabetes Type 2 Patients: a Randomised Controlled Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00277732

Enrollment

288

Registered

2006-01-16

Start date

2006-01-31

Completion date

2006-11-30

Last updated

2007-12-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Brief summary

The objective of this study is to evaluate the therapeutic effectiveness and cost-effectivity of pharmaceutical care for diabetes type 2 patients. Patients will be randomly allocated to the control group ( = no input from pharmacist) or intervention group ( = with pharmaceutical care at baseline and follow-up visits over 6 months).

Interventions

PROCEDUREPharmaceutical care at baseline and follow-up visits over 6 months

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

45 Years to 75 Years

Healthy volunteers

Inclusion criteria

* 45-75 years * Body Mass Index \>= 25 * Diabetes treatment for at least 12 months * Regular visitors of the participating community pharmacy

Exclusion criteria

* Patients taking only insulin (no oral antidiabetic drugs)

Design outcomes

Primary

Measure	Time frame
The difference between the study groups in the change of blood glucose and HbA1c	baseline and after 6 months

Secondary

Measure	Time frame
Therapy adherence	—
Body Mass Index	after 6 months
Periods of severe hypoglycemia	—
Knowledge about diabetes and treatment	after 6 months
Work days lost	—
Frequency of eye and foot examination	—
GP visits, emergency room visits and hospitalisations	—

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026